Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • AstraZeneca's three in...

    AstraZeneca's three in one inhaler helps COPD patients in trial

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-01-30T09:45:39+05:30  |  Updated On 16 Aug 2021 5:07 PM IST

    AstraZeneca said an inhaler for chronic obstructive pulmonary disease delivered improved lung function in a late-stage trial that could challenge GlaxoSmithKline's new three-in-one inhaler.


    The inhaler, PT010, showed "statistically significant" improvement in eight of nine main lung function goals in patients with moderate to very severe COPD, the company said.


    AstraZeneca said patients in the trial were given two inhalations twice a day of PT010, which is a single inhaler, fixed-dose triple combination therapy.


    There were no unexpected safety or tolerability signals for PT010 identified in the 24-week trial, it added.


    GSK's Trilogy Ellipta was the first once-daily triple medicine for COPD to market, putting Britain's biggest drugmaker ahead of rivals such as AstraZeneca and Novartis.


    GSK's inhaler, which it developed with Innovative, has already been approved for sale in the United States and Europe.


    "GSK is already on the market with its Trilogy Ellipta product so is well ahead, nevertheless PT010 should still find a place in the market," Liberum analysts said in a client note, adding the inhaler was not a critical product for AstraZeneca.


    AstraZeneca said it anticipated making regulatory submissions in Japan and China in the second half of this year, followed by possibly submitting it in the United States and Europe next year.




    (Reporting by Justin George Varghese in Bengaluru; Editing by Jason Neely and Mark Potter)



    AstraZenecaChronic Obstructive Pulmonary DiseaseCOPDGlaxoSmithKlineGSKinhalerNovartisPT010three-in-one inhalerTrilogy Ellipta
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok